Inspire Medical Systems, Inc. (INSP)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$63.08+1.51%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · INSP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue working with stakeholders to resolve coding and reimbursement challenges for Inspire V, aiming to restore revenue growth by 2027.
Stated as a priority in 3 of last 3 quarters. Management consistently highlights ongoing coding and reimbursement uncertainty impacting U.S. revenue, which contributed to a 7.6% revenue decline in 2026-Q2 to $200.6M from $217.1M in 2025-Q2. The company expects these challenges to persist through 2026 but anticipates returning to revenue growth in 2027. The trajectory shows persistent focus with limited revenue growth in the near term due to reimbursement issues.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'We continue to support customers through the evolving coding and reimbursement environment.'”
“CEO: 'We are continuing to work with key stakeholders to implement solutions that will resolve the coding and reimbursement uncertainty for Inspire V.'”
“CEO: 'We remain focused on our commitment to put the patient first and deliver strong patient outcomes despite reimbursement challenges.'”
Raise and meet full-year 2026 revenue guidance in the range of $835 million to $875 million despite reimbursement headwinds.
Stated as a priority in 3 of last 3 quarters. Revenue declined 7.6% year-over-year in 2026-Q2 to $200.6M from $217.1M in 2025-Q2, reflecting reimbursement challenges. Despite this, management raised full-year 2026 revenue guidance to $835M-$875M from prior $825M-$875M. The trajectory shows management maintaining growth targets amid near-term headwinds.
“Company is raising its previously announced revenue outlook to be in the range of $835 million to $875 million.”
“Company is revising its previously announced revenue outlook to be in the range of $825 million to $875 million.”
“Company is reaffirming its full year 2025 revenue guidance of $900 to $910 million.”
Improve and maintain adjusted operating margin in the range of 4% to 6% for full year 2026 through cost discipline and operational efficiency.
Stated as a priority in 2 of last 2 quarters. Adjusted operating margin improved from 0.2% in 2026-Q1 to 1.6% in 2026-Q2, below the full-year guidance range of 4% to 6%. Management raised margin guidance to 4%-6% for 2026, indicating ongoing efforts to improve cost discipline and operational efficiency. The trajectory shows progress but margin remains below target so far.
“Adjusted operating margin was 1.6% in 2026-Q2, up from prior periods.”
“Adjusted operating margin was 0.2% in 2026-Q1.”
Target adjusted diluted earnings per share in the range of $1.05 to $1.45 for full year 2026, reflecting improved profitability.
Stated as a priority in 2 of last 2 quarters. Adjusted diluted EPS was $0.10 in 2026-Q1 and $0.14 in 2026-Q2, below the full-year guidance range of $1.05 to $1.45. Management raised EPS guidance in August 2026, reflecting expectations for improved profitability. The trajectory shows early-year EPS below target but management expects improvement.
“Adjusted diluted EPS was $0.14 in 2026-Q2.”
“Adjusted diluted EPS was $0.10 in 2026-Q1.”
Execute Project Horizon to generate $30 million annualized growth investment capacity through restructuring and supply chain optimization.
Newly stated in 2026-Q2. Management announced Project Horizon to create $30 million in annualized growth investment capacity via restructuring and supply chain optimization, with expected pre-tax restructuring charges of $20 million to $25 million. This is an initial commitment with no prior quarters stating this plan, so delivery trajectory is yet to be determined.
“Announced strategic growth plan designed to unlock and redeploy $30 million for growth initiatives.”
Over the trailing year it converted -9.12x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.